Form 8.3 - Horizon Therapeutics plc

LONDON--()-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)

Millennium International Management LP

Company dealt in

Horizon Therapeutics plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

IE00BQPVQZ61

Date of dealing

19th May 2023

2. INTERESTS AND SHORT POSITIONS

a. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

4,786,804

(2.092%)

800

(0.000%)

(2) Derivatives (other than options)

-

-

(3) Options and agreements to purchase/sell

558,700

(0.244%)

1,548,600

(0.677%)

Total

5,345,504

(2.337%)

1,549,400

(0.677%)

b. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

 

Ap20

1. DEALINGS (Note 4)

a. Purchases and sales

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (USD) (Note 5)

Sale

172

101.44

Sale

160

101.59

Sale

200

101.65

Sale

100

101.69

Sale

17

101.58

Sale

69

101.57

Sale

154

101.54

Sale

139

100.75

Sale

200

101.56

Sale

200

101.48

Sale

100

101.07

Sale

100

101.05

Sale

12

101.04

Sale

200

100.97

Sale

1,192

100.89

Sale

187

100.87

Sale

894

101.15

Sale

100

100.60

Sale

200

100.83

Sale

542

101.45

Sale

101

101.65

Sale

300

101.57

Sale

20

100.49

Sale

100

100.44

Sale

2

100.82

Sale

15

100.63

Sale

15

101.53

Sale

100

101.52

Sale

1,065

100.96

Sale

16

100.80

Sale

301

101.54

Sale

20

100.41

Sale

300

101.63

Sale

200

101.68

Sale

157

100.75

Sale

5

100.72

Sale

20

100.48

Sale

5

100.79

Sale

1

100.81

Sale

300

100.77

Sale

2,734

101.41

Sale

384

100.90

Sale

100

101.77

Sale

100

101.40

Purchase

100

100.84

Purchase

100

100.87

Sale

1,038

101.45

Purchase

300

100.85

Purchase

500

100.80

Purchase

726

100.75

Purchase

300

101.56

Sale

10

101.56

Sale

1,374

101.29

Sale

1,794

101.30

Sale

310

101.13

Sale

623

101.03

Purchase

100

101.10

Sale

37

101.10

Sale

400

101.35

Sale

18

101.27

Purchase

100

101.48

Sale

12,153

101.48

Sale

560

101.39

Purchase

100

101.61

Sale

340

101.59

Sale

244

101.14

Sale

538

101.12

Sale

916

101.31

Sale

7,021

101.00

Sale

2,832

101.08

Sale

321

101.07

Sale

327

101.19

Sale

318

101.16

Sale

1,541

101.05

Sale

2,191

101.32

Purchase

1,000

101.24

Sale

117

101.24

Sale

1,896

101.04

Sale

497

101.18

Purchase

1,927

101.11

Sale

2,611

101.11

Sale

816

101.01

Purchase

2,590

101.06

Sale

1,556

101.06

Sale

272

101.22

Sale

335

100.97

Sale

21

100.91

Sale

180

100.88

Purchase

383

101.09

Sale

2,115

101.09

Sale

1,197

100.89

Sale

166

100.84

Sale

9

100.95

Sale

536

100.87

Sale

139

100.93

Sale

1,389

101.25

Sale

200

100.59

Sale

500

100.86

Sale

456

101.15

Purchase

605

100.74

Sale

48

100.74

Sale

559

100.83

Sale

856

101.33

Purchase

320

101.45

Purchase

1,200

101.65

Sale

144

101.65

Purchase

8,800

101.66

Purchase

300

101.69

Purchase

898

101.58

Sale

1

100.57

Sale

18

100.71

Sale

11

101.60

Purchase

15

101.96

Purchase

714

101.91

Sale

1,198

101.26

Purchase

919

101.57

Sale

700

101.57

Sale

120

100.85

Sale

3,700

100.69

Purchase

2,000

101.67

Sale

306

101.21

Sale

103

100.35

Sale

1,058

101.38

Sale

14

100.44

Sale

2

100.42

Sale

200

100.39

Sale

3,190

100.82

Sale

4

100.43

Purchase

731

101.50

Sale

100

101.50

Purchase

3,000

100.40

Sale

138

100.40

Sale

1

100.63

Sale

130

100.78

Sale

364

101.52

Sale

3,377

101.34

Sale

1,300

100.70

Purchase

1,065

100.96

Sale

146

100.96

Purchase

200

101.54

Sale

234

101.54

Sale

269

100.65

Sale

857

101.36

Sale

1

100.41

Sale

100

101.63

Purchase

500

101.73

Purchase

345

101.76

Purchase

2,048

101.55

Purchase

2

101.68

Purchase

2,597

101.28

Sale

1,005

101.28

Purchase

700

101.51

Sale

811

101.51

Sale

337

101.02

Purchase

300

101.72

Purchase

335

101.49

Sale

961

101.46

Sale

2,360

101.20

Purchase

2,595

100.75

Sale

92

100.75

Sale

120

100.48

Purchase

100

100.73

Sale

250

100.73

Sale

400

100.79

Sale

2,250

101.37

Sale

1,310

100.77

Sale

5,860

101.42

Sale

1,150

100.90

Purchase

12,403

101.47

Sale

200

101.86

Purchase

350

101.70

Sale

6

101.62

Sale

100

100.66

Sale

4

100.37

b. Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit (USD)

(Note 5)

 

 

 

 

c. Options transactions in respect of existing relevant securities

i. Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

(USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Put Option

Purchasing

2,300

100.00

American

6/16/2023

 

ii. Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

Call Option

25,000

100.00 USD

Put Option

50,200

110.00 USD

Call Option

25,000

95.00 USD

Put Option

10,000

105.00 USD

Put Option

800

110.00 USD

Put Option

4,400

110.00 USD

Put Option

40,600

110.00 USD

d. Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure

22nd May 2023

Contact name

Stephen Glasper

Telephone number

+44 203 398 2166

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making
disclosure:

Millennium International Management LP

Name of offeror/offeree in relation
to whose relevant securities the
disclosure relates:

Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of
relevant
security

Product
description
e.g. call
option

Written or
purchased

Number of
securities to
which option
or derivative
relates

Exercise
price
per unit

(USD)

Type
e.g.
American,
European
etc.

Expiry
date

IE00BQPVQZ61

Put Option

Purchased

300

80.00

American

1/17/2025

IE00BQPVQZ61

Put Option

Purchased

300

90.00

American

1/19/2024

IE00BQPVQZ61

Call Option

Purchased

1,200

110.00

American

8/18/2023

IE00BQPVQZ61

Call Option

Written

201,200

115.00

American

8/18/2023

IE00BQPVQZ61

Put Option

Written

50,000

80.00

American

8/18/2023

IE00BQPVQZ61

Put Option

Purchased

29,000

80.00

American

8/18/2023

IE00BQPVQZ61

Put Option

Purchased

3,600

105.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

10,900

105.00

American

7/21/2023

IE00BQPVQZ61

Call Option

Written

99,500

115.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

300,000

85.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

269,300

100.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

300

110.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

53,500

95.00

American

6/16/2023

IE00BQPVQZ61

Call Option

Written

300

110.00

American

7/21/2023

IE00BQPVQZ61

Put Option

Written

300

110.00

American

7/21/2023

IE00BQPVQZ61

Put Option

Written

400

110.00

American

8/18/2023

IE00BQPVQZ61

Call Option

Written

400

110.00

American

8/18/2023

IE00BQPVQZ61

Put Option

Written

250,000

70.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Purchased

250,000

85.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Purchased

50,000

90.00

American

6/16/2023

IE00BQPVQZ61

Put Option

Purchased

50,000

90.00

American

7/21/2023

IE00BQPVQZ61

Call Option

Purchased

50,000

100.00

American

6/16/2023

IE00BQPVQZ61

Call Option

Purchased

80,000

101.00

American

5/26/2023

IE00BQPVQZ61

Call Option

Purchased

125,300

110.00

American

6/16/2023

IE00BQPVQZ61

Call Option

Written

150,000

100.00

American

7/21/2023

IE00BQPVQZ61

Call Option

Written

80,000

105.00

American

6/16/2023

IE00BQPVQZ61

Call Option

Purchased

1,500

110.00

American

17/11/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET
Sequence Number: 1101200
Time of Receipt (offset from UTC): 20230522T142028+0100

Contacts

Millennium Partners, L.P.

Contacts

Millennium Partners, L.P.